Small company, big capital But TaiMed has been redoing Phase II trials on 355 for the nearly two years since it acquired the drug. The reason is a change in the HIV treatment guidelines implemented at the end of 2007 by the US Department of Health and Human Services.
小公司，大資本然而，從買下「355」的授權迄今 2 年，中裕仍停留在第二期臨床試驗的階段，主要原因是，美國衛生部於 2007 年年底修改了愛滋病的治療規範。